Galapagos NV Stock Price, News & Analysis (NASDAQ:GLPG)

$90.83 -0.66 (-0.72 %)
(As of 11/18/2017 03:49 AM ET)
Previous Close$90.83
Today's Range$91.47 - $90.76
52-Week Range$57.16 - $104.12
Volume38,397 shs
Average Volume91,825 shs
Market Capitalization$4.62288 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71

About Galapagos NV (NASDAQ:GLPG)

Galapagos NV logoGalapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:GLPG
  • CUSIP: N/A
  • Web: www.glpg.com
Debt:
  • Current Ratio: 8.05%
  • Quick Ratio: 8.05%
Sales & Book Value:
  • Annual Sales: $165.09 million
  • Price / Sales: 28.00
  • Cash Flow: $1.37 per share
  • Price / Cash: 66.24
  • Book Value: $23.94 per share
  • Price / Book: 3.79
Profitability:
  • Trailing EPS: ($0.92)
  • Net Income: $59.76 million
  • Net Margins: -22.26%
  • Return on Equity: -4.64%
  • Return on Assets: -3.45%
Misc:
  • Employees: 508
  • Outstanding Shares: 50,900,000
 

Frequently Asked Questions for Galapagos NV (NASDAQ:GLPG)

What is Galapagos NV's stock symbol?

Galapagos NV trades on the NASDAQ under the ticker symbol "GLPG."

When will Galapagos NV make its next earnings announcement?

Galapagos NV is scheduled to release their next quarterly earnings announcement on Friday, February, 23rd 2018. View Earnings Estimates for Galapagos NV.

Where is Galapagos NV's stock going? Where will Galapagos NV's stock price be in 2017?

8 equities research analysts have issued 1 year price targets for Galapagos NV's stock. Their predictions range from $98.00 to $124.00. On average, they anticipate Galapagos NV's share price to reach $111.83 in the next twelve months. View Analyst Ratings for Galapagos NV.

What are Wall Street analysts saying about Galapagos NV stock?

Here are some recent quotes from research analysts about Galapagos NV stock:

  • 1. According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (10/11/2017)
  • 2. Stifel Nicolaus analysts commented, "Aurinia reported 2Q17 financial results in an after market close press release." (8/11/2017)
  • 3. BTIG Research analysts commented, "Supports Thesis for Minimal Function CF Patients Yesterday, Vertex (VRTX, Not Rated) provided top-line results of the first triplet combination studies for Cystic Fibrosis patients with minimal function mutations, which represents 1/3 of the total patient population. Importantly, the triplet combinations also demonstrated improvements with the F508del homozygous population that exceed the clinical benefit of Orkambi. Overall, this first data for triplet therapies provides positive support for the use of two CFTR correctors within one daily regimen. The results from VRTX’s studies are positive for GLPG’s efforts conceptually, but given GLPG’s limited dataset to date, we continue to think that efforts within CF are a ‘show-me’ story. We maintain our Buy rating and $98 PT.   X-440 and VX-152 Triplet Combinations set a new hurdle rate for clinical efficacy: Although the timespans were relatively short, with 29 days studied with VX-440 and 15 days with VX-152, the +9.5% and +7.3% respective improvements of ppFEV1 are impressive within the F508del homozygous population given the study design had a 4 week run-in period with tezacaftor and ivacaftor. Furthermore, the statistically significant improvements in ppFEV1 in both VX-440 and VX-152 studies within the F508del/Min patient population is unprecedented, underscored by the previous failure of the tezacaftor + ivacaftor combination study." (7/20/2017)
  • 4. Cowen and Company analysts commented, "GLPG provided a broad pipeline update at an R&D day." (6/21/2017)
  • 5. Instinet analysts commented, "We are initiating coverage on Galapagos (GLPG) with a buy rating and $87 target price. We believe the company's rapidly advancing cystic fibrosis (CF) pipeline, partnered with AbbVie, will drive shares higher in the next 12 months. We also anticipate an increasing focus on filgotinib's opportunity in Crohn's disease, and ulcerative colitis (UC) in Phase 3 trials, may lead to upside in shares over the next 12-months. In our view, the current valuation is predominantly supported primarily by the blockbuster opportunity for the company's lead oral JAK1 inhibitor, filgotinib (partnered with Gilead), for the treatment of rheumatoid arthritis." (3/1/2017)

Who are some of Galapagos NV's key competitors?

Who are Galapagos NV's key executives?

Galapagos NV's management team includes the folowing people:

  • Onno van de Stolpe, Chief Executive Officer, Executive Director, Member of the Executive Committee
  • Bart Filius, Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer
  • , Bio & Compensation - 
  • Piet Wigerinck, Member of the Executive Committee, Chief Scientific Officer
  • , Bio & Compensation - 
  • Elizabeth Goodwin, VP Corporate Communications & Investor Relations
  • , Bio & Compensation - 
  • Walid Abi-Saab, Member of the Executive Committee, Chief Medical Officer
  • , Bio & Compensation - 
  • Andre Hoekema, Member of the Executive Committee, Chief Business Officer
  • , Bio & Compensation - 
  • Rajesh Parekh, Non-Executive Chairman of the Board
  • Harrold van Barlingen, Non-Executive Director
  • Katrine Bosley, Independent Non-Executive Director
  • , Bio & Compensation - 
  • Werner Cautreels, Non-Executive Independent Director

When did Galapagos NV IPO?

(GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Who owns Galapagos NV stock?

Galapagos NV's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (1.03%), Perceptive Advisors LLC (0.41%), Peregrine Capital Management LLC (0.21%), Jane Street Group LLC (0.14%), Alps Advisors Inc. (0.10%) and Dorsey Wright & Associates (0.10%). View Institutional Ownership Trends for Galapagos NV.

Who sold Galapagos NV stock? Who is selling Galapagos NV stock?

Galapagos NV's stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Perceptive Advisors LLC, Peregrine Capital Management LLC, Cubist Systematic Strategies LLC, P.A.W. Capital Corp and Macquarie Group Ltd.. View Insider Buying and Selling for Galapagos NV.

Who bought Galapagos NV stock? Who is buying Galapagos NV stock?

Galapagos NV's stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, JPMorgan Chase & Co., Dorsey Wright & Associates, Alps Advisors Inc., Citadel Advisors LLC, Belpointe Asset Management LLC, Bank of New York Mellon Corp and FNY Partners Fund LP. View Insider Buying and Selling for Galapagos NV.

How do I buy Galapagos NV stock?

Shares of Galapagos NV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galapagos NV's stock price today?

One share of Galapagos NV stock can currently be purchased for approximately $90.83.

How big of a company is Galapagos NV?

Galapagos NV has a market capitalization of $4.62288 billion and generates $165.09 million in revenue each year. The biotechnology company earns $59.76 million in net income (profit) each year or ($0.92) on an earnings per share basis. Galapagos NV employs 508 workers across the globe.

How can I contact Galapagos NV?

Galapagos NV's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at ir@glpg.com.


MarketBeat Community Rating for Galapagos NV (NASDAQ GLPG)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  293
MarketBeat's community ratings are surveys of what our community members think about Galapagos NV and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Galapagos NV (NASDAQ:GLPG)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $111.83 (23.12% upside)

Consensus Price Target History for Galapagos NV (NASDAQ:GLPG)

Price Target History for Galapagos NV (NASDAQ:GLPG)

Analysts' Ratings History for Galapagos NV (NASDAQ:GLPG)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/29/2017Stifel NicolausReiterated RatingBuy$120.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$92.00 -> $123.00N/AView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform$98.00MediumView Rating Details
8/11/2017NomuraBoost Price TargetBuy$108.00 -> $124.00LowView Rating Details
8/10/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
7/26/2017BTIG ResearchReiterated RatingBuy$98.00MediumView Rating Details
7/7/2017Janney Montgomery ScottUpgradeSell -> NeutralLowView Rating Details
6/22/2017InstinetReiterated RatingBuy$121.00 -> $108.00LowView Rating Details
10/18/2016Goldman Sachs Group, Inc. (The)UpgradeNeutral -> BuyN/AView Rating Details
6/17/2016Credit Suisse GroupReiterated RatingHold$48.00N/AView Rating Details
12/17/2015Bryan, Garnier & CoBoost Price TargetBuy$52.00 -> $64.00N/AView Rating Details
12/8/2015KBC SecuritiesUpgradeBuyN/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Galapagos NV (NASDAQ:GLPG)

Earnings by Quarter for Galapagos NV (NASDAQ:GLPG)

Earnings History by Quarter for Galapagos NV (NASDAQ GLPG)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2018        
11/13/2015Q3($0.80)$11.46 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Galapagos NV (NASDAQ:GLPG)
Current Year EPS Consensus Estimate: $-2.58 EPS
Next Year EPS Consensus Estimate: $-2.94 EPS

Dividends

Dividend History for Galapagos NV (NASDAQ:GLPG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galapagos NV (NASDAQ GLPG)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Galapagos NV (NASDAQ GLPG)

Source:
DateHeadline
ADRDs Underlying Holdings Could Mean 10% Gain PotentialADRD's Underlying Holdings Could Mean 10% Gain Potential
www.nasdaq.com - November 14 at 7:41 PM
Galapagos: Strong Buy From Europe - Seeking AlphaGalapagos: Strong Buy From Europe - Seeking Alpha
seekingalpha.com - November 8 at 8:05 AM
Galapagos: Strong Buy From Europe - Seeking AlphaGalapagos: Strong Buy From Europe - Seeking Alpha
seekingalpha.com - November 8 at 8:05 AM
Galapagos NV (GLPG): Thoughts From NACFC - Stifel - StreetInsider.comGalapagos NV (GLPG): Thoughts From NACFC - Stifel - StreetInsider.com
www.streetinsider.com - November 8 at 8:05 AM
Galapagos NV (GLPG): Thoughts From NACFC - Stifel - StreetInsider.comGalapagos NV (GLPG): Thoughts From NACFC - Stifel - StreetInsider.com
www.streetinsider.com - November 8 at 8:05 AM
Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 studyConsistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study
feeds.benzinga.com - November 5 at 9:55 AM
Galapagos NV :GLPG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Galapagos NV :GLPG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 9:59 AM
Galapagos NV: Galapagos moving forward in CF programs at NACFC 2017Galapagos NV: Galapagos moving forward in CF programs at NACFC 2017
www.finanznachrichten.de - November 2 at 8:50 PM
Galapagos moving forward in CF programs at NACFC 2017Galapagos moving forward in CF programs at NACFC 2017
feeds.benzinga.com - November 2 at 3:31 AM
Galapagos NV (GLPG) Given Average Rating of "Buy" by BrokeragesGalapagos NV (GLPG) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 1 at 5:34 PM
Galapagos NV (GLPG) PT Raised to $118 at BTIG - StreetInsider.comGalapagos NV (GLPG) PT Raised to $118 at BTIG - StreetInsider.com
www.streetinsider.com - October 31 at 1:00 AM
Galapagos NV: Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipelineGalapagos NV: Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline
www.finanznachrichten.de - October 28 at 6:05 AM
Galapagos NV Q3 revenues up 64%; updates guidanceGalapagos NV Q3 revenues up 64%; updates guidance
seekingalpha.com - October 28 at 6:05 AM
Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline - GlobeNewswire (press release)Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline - GlobeNewswire (press release)
globenewswire.com - October 27 at 12:27 AM
Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipelineGalapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline
finance.yahoo.com - October 27 at 12:27 AM
Critical Comparison: Puma Biotechnology (PBYI) and Galapagos NV (GLPG)Critical Comparison: Puma Biotechnology (PBYI) and Galapagos NV (GLPG)
www.americanbankingnews.com - October 23 at 8:30 PM
Galapagos NV (GLPG) Upgraded to Hold by Zacks Investment ResearchGalapagos NV (GLPG) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - October 11 at 10:26 PM
ETFs with exposure to Galapagos NV : October 5, 2017ETFs with exposure to Galapagos NV : October 5, 2017
finance.yahoo.com - October 10 at 3:18 PM
Galapagos NV (GLPG) Receives Consensus Rating of "Buy" from BrokeragesGalapagos NV (GLPG) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 7 at 6:50 PM
Galapagos NV (GLPG) Stock Rating Reaffirmed by Morgan StanleyGalapagos NV (GLPG) Stock Rating Reaffirmed by Morgan Stanley
www.americanbankingnews.com - October 7 at 12:22 PM
ETFs with exposure to Galapagos NV : October 5, 2017ETFs with exposure to Galapagos NV : October 5, 2017
finance.yahoo.com - October 5 at 7:05 PM
Galapagos Pops After Eczema Drug Shows Promise Vs. RegeneronGalapagos Pops After Eczema Drug Shows Promise Vs. Regeneron
finance.yahoo.com - October 2 at 2:00 PM
Galapagos NV (GLPG) Sees Large Decline in Short InterestGalapagos NV (GLPG) Sees Large Decline in Short Interest
www.americanbankingnews.com - September 30 at 2:34 AM
Form 6-K GALAPAGOS NV For: Sep 27Form 6-K GALAPAGOS NV For: Sep 27
www.streetinsider.com - September 27 at 10:15 PM
Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patientsGalapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients
feeds.benzinga.com - September 27 at 3:04 AM
ETFs with exposure to Galapagos NV : September 19, 2017ETFs with exposure to Galapagos NV : September 19, 2017
finance.yahoo.com - September 19 at 7:06 PM
Galapagos NV :GLPG-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017Galapagos NV :GLPG-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 6:37 PM
Galapagos NV (GLPG) PT Raised to $120 at Stifel on Positive KOL Feedback on GLPG1690 for IPF - StreetInsider.comGalapagos NV (GLPG) PT Raised to $120 at Stifel on Positive KOL Feedback on GLPG1690 for IPF - StreetInsider.com
www.streetinsider.com - September 16 at 6:25 PM
Galapagos NV (GLPG) Price Target Raised to $120.00Galapagos NV (GLPG) Price Target Raised to $120.00
www.americanbankingnews.com - September 15 at 7:28 AM
Galapagos NV (GLPG) Coverage Initiated by Analysts at Royal Bank Of CanadaGalapagos NV (GLPG) Coverage Initiated by Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 9:50 PM
Galapagos NV (GLPG) Given Consensus Recommendation of "Buy" by AnalystsGalapagos NV (GLPG) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 12 at 6:26 PM
Galapagos NV (GLPG) Receives Average Recommendation of "Buy" from BrokeragesGalapagos NV (GLPG) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 18 at 6:32 PM
3 Things In Biotech You Should Learn Today: August 14, 2017 - Seeking Alpha3 Things In Biotech You Should Learn Today: August 14, 2017 - Seeking Alpha
seekingalpha.com - August 14 at 7:27 PM
Galapagos NV (NASDAQ:GLPG) Upgraded at Stifel NicolausGalapagos NV (NASDAQ:GLPG) Upgraded at Stifel Nicolaus
www.americanbankingnews.com - August 13 at 7:14 PM
Nomura Boosts Galapagos NV (GLPG) Price Target to $124.00Nomura Boosts Galapagos NV (GLPG) Price Target to $124.00
www.americanbankingnews.com - August 12 at 10:56 PM
Stifel Upgrades Galapagos NV (GLPG) to Buy - StreetInsider.comStifel Upgrades Galapagos NV (GLPG) to Buy - StreetInsider.com
www.streetinsider.com - August 12 at 12:37 AM
Morgan Stanley Expects Galapagos Shares To Rise 10%Morgan Stanley Expects Galapagos Shares To Rise 10%
www.benzinga.com - August 11 at 12:12 AM
Galapagos NV (GLPG) Says GLPG1690 Halts Disease Progression in IPF Patients in FLORA Phase 2a TrialGalapagos NV (GLPG) Says GLPG1690 Halts Disease Progression in IPF Patients in FLORA Phase 2a Trial
www.streetinsider.com - August 11 at 12:12 AM
Morgan Stanley Reiterates "Overweight" Rating for Galapagos NV (NASDAQ:GLPG)Morgan Stanley Reiterates "Overweight" Rating for Galapagos NV (NASDAQ:GLPG)
www.americanbankingnews.com - August 10 at 11:34 PM
Cowen and Company Reaffirms "Buy" Rating for Galapagos NV (NASDAQ:GLPG)Cowen and Company Reaffirms "Buy" Rating for Galapagos NV (NASDAQ:GLPG)
www.americanbankingnews.com - August 10 at 4:32 PM
GLPGs FLORA Blooms, DVAX, ESPR Price Offering, SGMO Abuzz, HRTX On Track - NasdaqGLPG's FLORA Blooms, DVAX, ESPR Price Offering, SGMO Abuzz, HRTX On Track - Nasdaq
www.nasdaq.com - August 10 at 5:24 AM
GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trialGLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial
finance.yahoo.com - August 9 at 7:16 PM
Is a Surprise Coming for Galapagos (GLPG) This Earnings Season?Is a Surprise Coming for Galapagos (GLPG) This Earnings Season?
finance.yahoo.com - August 3 at 9:12 PM
Galapagos NV (NASDAQ:GLPG) Expected to Post FY2017 Earnings of ($2.23) Per ShareGalapagos NV (NASDAQ:GLPG) Expected to Post FY2017 Earnings of ($2.23) Per Share
www.americanbankingnews.com - August 2 at 10:38 AM
$27.35 Million in Sales Expected for Galapagos NV (NASDAQ:GLPG) This Quarter$27.35 Million in Sales Expected for Galapagos NV (NASDAQ:GLPG) This Quarter
www.americanbankingnews.com - August 1 at 9:14 AM
Solid financials support R&D progress - GlobeNewswire (press release)Solid financials support R&D progress - GlobeNewswire (press release)
globenewswire.com - July 28 at 5:44 AM
Solid financials support R&D progress - NasdaqSolid financials support R&D progress - Nasdaq
www.nasdaq.com - July 27 at 7:37 PM
Servier licenses GLPG1972 in osteoarthritis from GalapagosServier licenses GLPG1972 in osteoarthritis from Galapagos
finance.yahoo.com - July 27 at 7:37 PM
Solid financials support R&D progressSolid financials support R&D progress
finance.yahoo.com - July 27 at 7:37 PM
Galapagos NV (GLPG) Earns Buy Rating from BTIG ResearchGalapagos NV (GLPG) Earns Buy Rating from BTIG Research
www.americanbankingnews.com - July 26 at 4:31 PM

Social Media

Financials

Financials are not available for this stock.

Chart

Galapagos NV (NASDAQ GLPG) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.